Phase 2, Double-Blind, Randomized, Controlled Multi-Center Clinical Trial of the Safety and Efficacy of Transplanted Fetal Porcine Cells in Patients With Parkinson's Disease.

This study has been completed.
Sponsor:
Collaborator:
Diacrin/Genzyme Corporation LLC
Information provided by:
Genzyme, a Sanofi Company
ClinicalTrials.gov Identifier:
NCT00226460
First received: September 23, 2005
Last updated: June 18, 2008
Last verified: September 2005
  Purpose

The purpose of this study was to evaluate the differences in safety and efficacy between Parkinson's disease patients who either received transplantation of fetal porcine cells or placebo treatment.


Condition Intervention Phase
Parkinson's Disease
Drug: Fetal porcine cells, Neurocell-PD
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Double-Blind
Primary Purpose: Treatment

Resource links provided by NLM:


Further study details as provided by Genzyme, a Sanofi Company:

Primary Outcome Measures:
  • change in UPDRS

Secondary Outcome Measures:
  • change in PET scan

Study Start Date: August 1997
Estimated Study Completion Date: January 2001
  Eligibility

Ages Eligible for Study:   40 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • The patient has idiopathic Parkinson's disease. a) with bradykinesia and either rest tremor or rigidity, b) history of asymmetry of Parkinson's disease signs, c) history of progression of Parkinson's disease signs, d) no other suspected cause of Parkinson's disease, e) the patient is L-DOPA responsive (based on the Treating Investigator's clinical judgment, the patient demonstrates a predictable ON response after the first daily dose of L-DOPA)
  • The patient has had Parkinson's disease for at least 5 years (from onset of symptoms).
  • The patient demonstrates unequivocal Clinical Off periods.
  • Patient has been on a stable regimen of L-DOPA and any other anti-Parkinsonian medications for at least one month prior to start of screening.
  • The patient demonstrates L-DOPA-or dopamine agonist-induced dyskinesias.
  • The patient's age is 40-70.
  • The patient is currently under "optimal medical therapy", as determined by the Treating Investigator.
  • The patient has had a UPDRS assessment as per a modified CAPIT protocol at screening and the total UPDRS score in the defined OFF state was at least 60.
  • If the patient is a woman of child bearing potential, she must not be nursing and an adequate form of birth control must be used for the duration of this trial.
  • The patient has a normal chest x-ray and does not exhibit any signs or symptoms of coronary artery disease (on exam or on EKG) dysrhythmia (in order for surgery to be safely performed).
  • The patient is able to understand and is willing to comply with study requirements; this may include travel within or outside the United States for neuroimaging testing and surgery. It will be necessary for a companion to travel with the patient.
  • The patient is able to provide written informed consent.
  • The patient understands that the Sponsor recommends that all patients in this trial avoid pregnancy and minimize the sharing of secretions with sexual partners.
  • The patient is willing to participate in the life-long xenotransplantation registry.

Exclusion Criteria:

  • The patient has a likely alternative diagnosis for Parkinsonism based on history, physical examination or laboratory testing. Atypical Parkinsonian variants (such as Shy-Drager, olivopontocerebellar atrophy, progressive supranuclear palsy and striatonigral degeneration) and secondary Parkinsonism (e.g., secondary to trauma or metabolic abnormalities; history of encephalitis, oculogyric crises or use of dopaminergic antagonists/depleting drugs) will be excluded.
  • The patient has had a prior cranial neurosurgical procedure.
  • The patient has MRI or CT evidence of abnormalities which could lead to Parkinsonism or make the patient an unsuitable neurosurgical candidate.
  • The patient has a history of intracranial pathology (e.g., tumor, vascular malformation) that might make the patient an unsuitable neurosurgical candidate.
  • The patient has a pre-existing medical condition that may interfere with the evaluation of the safety and/or effectiveness of the study agent or prevent study completion (e.g.:, symptomatic cardiac disease, impaired renal function or seizure disorder).
  • The patient has a known sensitivity to products of porcine origin (e.g. pork).
  • The patient has a known steroid or cyclosporine intolerance.
  • The patient has significant cognitive impairment; specifically, a MMSE score of < 25, and, in the investigators judgment, the patient is demented.
  • The patient has a Hamilton Depression score of > 16.
  • The patient has hallucinations, delusions, psychosis or chronic psychiatric illness, with the exception of mild, L-DOPA induced hallucinations, or those caused by concomitant medications, which resolve with dose adjustment.
  • The patient has a positive response to a tuberculin skin test (with the exception of patients who have either been inoculated for TB, or treated for the disease in the past).
  • The patient has been treated during the 6 months prior to Screening with dopaminergic antagonists.
  • (Females only) The patient is nursing or pregnant.
  • The patient has taken tolcapone within 6 weeks of the Screening UPDRS exam.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00226460

Locations
United States, Florida
PD and Movement Disorders, University of South Florida
Tampa, Florida, United States, 33606
Sponsors and Collaborators
Genzyme, a Sanofi Company
Diacrin/Genzyme Corporation LLC
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00226460     History of Changes
Other Study ID Numbers: PD96-1101
Study First Received: September 23, 2005
Last Updated: June 18, 2008
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Parkinson Disease
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases

ClinicalTrials.gov processed this record on July 24, 2014